New York, NY - (ACCESSWIRE) - 11/11/2013 - Growing Stock Report initiates its NASDAQ Active Stock Weekly Watch List adding Zalicus Inc. (NASDAQ:ZLCS), CollabRx, Inc. (NASDAQ:CLRX), Discovery Laboratories Inc. (NASDAQ:DSCO) and Galena Biopharma, Inc. (NASDAQ:GALE).
Zalicus Inc. (NASDAQ:ZLCS) a biopharmaceutical company that engages in the discovery and development of novel treatments for patients suffering from pain is currently down (-71.43%) on 7,085,629 shares traded after Zalicus reported Z160 did not meet the primary endpoint in either of the Phase 2 clinical studies; company to discontinue Z160 clinical development. Zalicus Inc. (NASDAQ:ZLCS) is currently down (-86.11%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Zalicus Inc. (NASDAQ:ZLCS)Click Here: http://www.growingstockreport.com/Survey.aspx?stock=ZLCS&SubId=AW
CollabRx, Inc. (NASDAQ:CLRX) a company that offers cloud-based expert systems to inform health care decision-making is currently up (+42.26%) on 983,098 shares traded after CollabRx announced a multi-year, non-exclusive agreement with Quest Diagnostics related to medical annotation for new next-generation sequencing test services for cancer. CollabRx, Inc. (NASDAQ:CLRX) is currently up (+125%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about CollabRx, Inc. (NASDAQ:CLRX)
Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CLRX&SubId=AW
Discovery Laboratories Inc. (NASDAQ:DSCO) a specialty biotechnology company that focuses on developing products for critical care patients with respiratory disease and care in pulmonary medicine is currently up (+6.42%) on 733,919 shares traded as Discovery Laboratories, Inc. will host a conference call at 10:00 a.m. ET on Wednesday, November 13, 2013 to discuss the third quarter financial results and other business updates. Discovery Laboratories Inc. (NASDAQ:DSCO) is currently up (+49.33%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Discovery Laboratories Inc. (NASDAQ:DSCO)
Click Here: http://www.growingstockreport.com/Survey.aspx?stock=DSCO&SubId=AW
Galena Biopharma, Inc. (NASDAQ:GALE) a biopharmaceutical company that focuses on developing oncology treatments to address major unmet medical needs to advance cancer care is currently up (+2.96%) on 972,788 shares traded after Galena Biopharma Announced Initial Results From the Folate Binding Protein Vaccine Phase 1 Trial at the Society for Immunotherapy of Cancer Conference. Galena Biopharma, Inc. (NASDAQ:GALE) is currently up (+99.19%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Galena Biopharma, Inc. (NASDAQ:GALE)
Click Here: http://www.growingstockreport.com/Survey.aspx?stock=GALE&SubId=AW
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.growingstockreport.com/
Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Contact Info:Growing Stock Report
[email protected]